By Jeff Brown, editor, Exponential Tech Investor We’re on the cusp of a complete reordering of health care… and at the very beginning of a major bull run in biotech. It all has to do with an emerging technology trend called precision medicine. Let me explain… These days, we typically wait until we feel sick before we seek medical treatment. Then, we visit a hospital, where our symptoms are treated with varying degrees of success. Very often, each patient is treated with a “one size fits all” therapy. This approach to medicine is reactionary. In the very near future, medicine will be proactive and personalized. We will have our genome – our genetic “blueprint” – sequenced to identify mutations in our genetic code that lead to disease. Then, thanks to CRISPR genetic editing technology, we’ll be able to fix these mutations – these “typos” – in our DNA. As a reminder, CRISPR can edit our genetic code as if it were software. And thanks to CRISPR, we will cure diseases in patients years before symptoms ever present themselves. | Recommended Link | | Teeka Tiwari Voted Most Trusted Man in Cryptos
For more than 25 years, Teeka Tiwari has built an impressive resume in the upper echelons of the financial world. Recently, that has included a successful run making profitable recommendations during the 2017 Crypto Boom. And warning people ahead of the 2018 Crypto Bust.
That's why he was recently voted by more than 130,000 crypto enthusiasts… From 135 countries… As the Most Trusted Man in Cryptos.
Now, Teeka has a new prediction… He believes cryptos are at the beginning of a long-term surge upwards within the next 3-to-6 months. To find out how you can learn more, and take advantage of Teeka's crypto knowledge… Click here. | | | | Eye-Opening Progress This technology saw a number of remarkable developments last year. In November, I attended a biotechnology conference, the STAT Summit. It was the first year the event was held, and it was fantastic. One of the most incredible presentations came from Vertex Pharmaceuticals (VRTX) CEO Jeffrey Leiden. Vertex has been working with a company called CRISPR Therapeutics (CRSP) on a therapy for sickle cell disease and beta thalassemia. Bad mutations in the hemoglobin gene cause these blood disorders. The therapy is CTX001. Leiden talked about how two patients have been treated with CTX001 so far – one with sickle cell disease and the other with beta thalassemia. And the results have been phenomenal. The beta thalassemia patient had not needed a blood transfusion in nine months. This is amazing because patients with this disease typically need blood transfusions every 2–4 weeks. And the sickle cell patient had not suffered a crisis in four months. And Leiden stated directly, “We have essentially cured these diseases. We have cracked the biology of sickle cell and beta [thalassemia].” Of course, it is not approved by the Food and Drug Administration (FDA) yet. The next step for Vertex is to expand the clinical trials to another 45 patients. I’m expecting identical results compared to the first two patients. But going off of Leiden’s comments, it appears CRISPR technology has cured these diseases caused by genetic mutations. | Recommended Link | | Sell Stocks Now: The Ultra-Rich Are Getting Out Fast
With President Trump being impeached… The U.S.-China trade war rattling the markets… And the U.S. Government $22 trillion in debt… Do you believe we can continue this 'Endless Bull Market'?
If you want to know what's really going on, there's only one thing to do… Look at what the ultra-wealthy are doing with their money… And they're getting out fast. To protect your wealth — and grow richer in the future, watch this urgent video now. Click Here to Watch This Urgent Video Alert. | | | | What’s Next So beta thalassemia and sickle cell disease were the first two, but I predict that CRISPR will cure at least five more diseases caused by genetic mutations in 2020. To be clear, I don’t expect that five therapies will be approved by the FDA in 2020. But I believe at least five CRISPR therapies will demonstrate in either preclinical or clinical trials that they have cured the diseases they were meant to cure. The novel therapies for these genetically caused diseases will absolutely continue this year. We are still just at the beginning. And once the applications of CRISPR are well understood, we’re going to continue to see an explosion of investment in this area. So investors should pay close attention to biotech this year. We’re at the very beginning of a multiyear bull market for the biotech space. I mean, just think about it… We have a combination of advanced diagnostic technologies coupled with computer processing power, artificial intelligence, and machine learning. And we have an incredible genetic editing platform like CRISPR. On top of that, we saw record levels of private investments in the biotechnology sector in 2019. This is all going to lead to a multiyear boom in biotech that will really start in 2020. 
We will see an explosion of therapies. There will also be a shorter time between drug discovery and FDA approval because of all these tools we have now. We’re going to also have better-quality drugs that will have fewer side effects and will be highly personalized for each patient. And once Wall Street sees this, what is it going to do? It will invest more in that space because it finally understands what incredible technological advancements are happening. It’s going to be like dumping fuel on a fire. Plus, I predict several early-stage companies developing CRISPR therapies will go public. I have a list of companies I think might. We’ll just have to wait and see. But either way, we’re going to have some great new investment opportunities in this space in 2020. Regards, Jeff Brown
Editor, Exponential Tech Investor P.S. Like I said before, we’re at the beginning of a multiyear bull run in biotech. And the best CRISPR companies will be leading the charge. My readers are already making money on this trend. As mentioned above, just this past Tuesday, we booked a 339% gain on a biotech company that uses CRISPR technology. However, that doesn’t mean it’s too late to get in on this trend before it takes off in 2020. Right now, a genetic editing company is working hard to cure a form of genetic blindness. That’s right. This company is working to literally cure blindness. The trial results are expected early this year. And I have good reason to believe they will be positive. And when that happens, the share price of this small-cap stock will skyrocket. There’s still time to get positioned, but not much. Go right here while you have the chance.
Reader Mailbag Today in the mailbag, several readers thank our founder Doug Casey for warning of the potential dangers of facial recognition technology: I can’t get enough of Doug Casey. His thinking is refreshing and real. The world can change so rapidly now, we shouldn’t ever be caught thinking: “I didn’t see that coming!” Great perspective and real views. – Chris I just read the essay on facial recognition that warns about excessive cell phone use. This is ironic because I read all the Casey Research stuff on my phone. Watch out for what you ask for, you might get it! While I’m at it, I just want to tell the government monitor who’s reading this that I’m not subversive. I just read Casey for entertainment! – Willard Meanwhile, after Doug shared his opinion on Elon Musk’s new Cybertruck, other readers chimed in with their own thoughts: Doug, to me the Cybertruck looks like it was put together in someone’s garage. Or perhaps something from a Mad Max movie. I enjoyed the column. Thanks. – Roy You won't see many of these trucks actually on a job site, until it is modified to accept a utility bed. And, of course, that would ruin the whole idea. – Roger And finally, one reader shared his appreciation for the honest and insightful writing from Crisis Investing editor Nick Giambruno: Hello, Nick. I just read your December Crisis Investing report. Thank you! Obviously, it is not easy to write interesting reports on a monthly basis and be right so often. You guys are doing a great job! Thanks and kind regards from Switzerland. – Daniel We love hearing from our readers! Keep sending your thoughts to feedback@caseyresearch.com.
In Case You Missed It… [BREAKING NEWS] You Do NOT Bet $100 Million On A Long Shot A consortium of 14 of the world's savviest biotech investors are all in on this small-cap. Including the former science advisor of the world's richest man: Bill Gates. All told, they've invested over $100 million. Over the next 12 months, once-in-a-lifetime gains of 3,277%, 5,940%, or 10,645% are not out of the question… if you act immediately. Here's how to join them with one simple move. Get the details here. 
| 
Tidak ada komentar:
Posting Komentar